Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.

[1]  Judy H. Cho,et al.  Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. , 2019, JAMA.

[2]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[3]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[4]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[5]  F. Salvi,et al.  Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure , 2018, European journal of heart failure.

[6]  D. Keohane,et al.  Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy , 2017, European journal of neurology.

[7]  M. B. Sultan,et al.  Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy , 2016, Clinical Medicine Insights. Cardiology.

[8]  Sanjiv J. Shah,et al.  Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). , 2017, Circulation. Heart failure.

[9]  C. Rapezzi,et al.  Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. , 2017, Journal of the American College of Cardiology.

[10]  R. Falk,et al.  Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. , 2017, Journal of the American College of Cardiology.

[11]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[12]  Scott M. Williams,et al.  The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa , 2016, Molecular genetics & genomic medicine.

[13]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[14]  M. Maurer,et al.  Transthyretin Cardiac Amyloidosis in Black Americans , 2016, Circulation. Heart failure.

[15]  S. Frusconi,et al.  The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience , 2016, Journal of cardiovascular medicine.

[16]  M. Benson,et al.  A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis , 2015, Neurology and Therapy.

[17]  J. Buxbaum,et al.  Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African–Americans , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[18]  E. Boerwinkle,et al.  The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.

[19]  M. Maurer,et al.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. , 2013, Aging health.

[20]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[21]  M. Puhan,et al.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[22]  J. Berk,et al.  Transthyretin (TTR) Cardiac Amyloidosis , 2012, Circulation.

[23]  R. Falk,et al.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). , 2012, American heart journal.

[24]  J. Casillas,et al.  DETERMINING THE MINIMAL CLINICALLY IMPORTANT 1 DIFFERENCE FOR THE SIX-MINUTE WALK TEST AND THE 2002 METER FAST WALK TEST DURING CARDIAC REHABILITATION 3 PROGRAM IN CORONARY ARTERY DISEASE PATIENTS AFTER 4 ACUTE CORONARY SYNDROME , 2017 .

[25]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[26]  H. Krumholz,et al.  Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.

[27]  Cynthia D. Brown,et al.  Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test , 2005, COPD.

[28]  D. Schoenfeld,et al.  Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.

[29]  H. Staunton,et al.  Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. , 1995, Journal of neurology, neurosurgery, and psychiatry.